{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:57:50Z","timestamp":1788501470998,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000691","name":"Academy of Medical Sciences","doi-asserted-by":"publisher","award":["SBF008\\1092"],"award-info":[{"award-number":["SBF008\\1092"]}],"id":[{"id":"10.13039\/501100000691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Chronic pain states remain challenging to control with current drug therapies. Here, we demonstrate that a single dose of psilocybin produces a sustained anti-nociceptive effect in chronic neuropathic pain models in male and female mice, mediated primarily by 5-HT\n                    <jats:sub>2A<\/jats:sub>\n                    receptors. Critically, psilocybin significantly potentiates the analgesic efficacy of gabapentin, a standard-of-care treatment, representing the first preclinical evidence that a psychedelic can serve as a pain-network primer for existing analgesics. This finding represents a novel therapeutic strategy with potential clinical application, particularly for the 30-50% of neuropathic pain patients who fail gabapentin monotherapy. Our data demonstrate that a single psilocybin injection produces sustained month-long changes that enhance gabapentin efficacy in a preclinical model of human pain. Together, these findings indicate that psilocybin both acutely enhances analgesia and induces lasting changes that amplify gabapentin efficacy weeks later. Such a translation is notable in chronic pain management, where most analgesics require chronic dosing and lose efficacy through tolerance. These findings establish psilocybin as a potential therapeutic addition for pain management by enabling longer-lasting changes in pain-processing networks and enhancing the utility of established treatments.\n                  <\/jats:p>","DOI":"10.1038\/s42003-026-10065-7","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T16:53:43Z","timestamp":1777049623000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesia"],"prefix":"10.1038","volume":"9","author":[{"given":"Tatum","family":"Askey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Allen-Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniil","family":"Luzyanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Lasrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Gilmour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9453-5505","authenticated-orcid":false,"given":"Stephen P.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8741-5094","authenticated-orcid":false,"given":"Francesco","family":"Tamagnini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maqsood","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0927-6567","authenticated-orcid":false,"given":"Maria","family":"Maiar\u00fa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"10065_CR1","doi-asserted-by":"publisher","first-page":"e273","DOI":"10.1016\/j.bja.2019.03.023","volume":"123","author":"SEE Mills","year":"2019","unstructured":"Mills, S. E. E., Nicolson, K. P. & Smith, B. H. Chronic pain: a review of its epidemiology and associated factors in population-based studies. Br. J. Anaesth. 123, e273\u2013e283 (2019).","journal-title":"Br. J. Anaesth"},{"key":"10065_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup, N. B. et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 14, 162\u2013173 (2015).","journal-title":"Lancet Neurol."},{"key":"10065_CR3","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJMra1507771","volume":"374","author":"ND Volkow","year":"2016","unstructured":"Volkow, N. D. & McLellan, A. T. Opioid abuse in chronic pain \u2014 misconceptions and mitigation strategies. N. Engl. J. Med. 374, 1253\u20131263 (2016).","journal-title":"N. Engl. J. Med"},{"key":"10065_CR4","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1001\/archinte.163.20.2433","volume":"163","author":"MJ Bair","year":"2003","unstructured":"Bair, M. J., Robinson, R. L., Katon, W. & Kroenke, K. Depression and pain comorbidity: a literature review. Arch. Intern. Med. 163, 2433 (2003).","journal-title":"Arch. Intern. Med"},{"key":"10065_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1021\/cn300138m","volume":"4","author":"JB Hanks","year":"2013","unstructured":"Hanks, J. B. & Gonz\u00e1lez-Maeso, J. Animal models of serotonergic psychedelics. ACS Chem. Neurosci. 4, 33\u201342 (2013).","journal-title":"ACS Chem. Neurosci."},{"key":"10065_CR6","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","volume":"44","author":"MK Madsen","year":"2019","unstructured":"Madsen, M. K. et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology 44, 1328\u20131334 (2019).","journal-title":"Neuropsychopharmacology"},{"key":"10065_CR7","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris, R. et al. Trial of psilocybin versus escitalopram for depression. N. Engl. J. Med. 384, 1402\u20131411 (2021).","journal-title":"N. Engl. J. Med."},{"key":"10065_CR8","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41591-022-01744-z","volume":"28","author":"RE Daws","year":"2022","unstructured":"Daws, R. E. et al. Increased global integration in the brain after psilocybin therapy for depression. Nat. Med. 28, 844\u2013851 (2022).","journal-title":"Nat. Med."},{"key":"10065_CR9","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1038\/s41593-025-02068-0","volume":"28","author":"A Hammo","year":"2025","unstructured":"Hammo, A., Wisser, S. & Cichon, J. Single-dose psilocybin rapidly and sustainably relieves allodynia and anxiodepressive-like behaviors in mouse models of chronic pain. Nat. Neurosci. 28, 2285\u20132295 (2025).","journal-title":"Nat. Neurosci."},{"key":"10065_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/13554794.2018.1468469","volume":"24","author":"V Ramachandran","year":"2018","unstructured":"Ramachandran, V., Chunharas, C., Marcus, Z., Furnish, T. & Lin, A. Relief from intractable phantom pain by combining psilocybin and mirror visual-feedback (MVF). Neurocase 24, 105\u2013110 (2018).","journal-title":"Neurocase"},{"key":"10065_CR11","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s13311-020-00962-y","volume":"18","author":"EAD Schindler","year":"2021","unstructured":"Schindler, E. A. D. et al. Exploratory controlled study of the migraine-suppressing effects of psilocybin. Neurotherapeutics 18, 534\u2013543 (2021).","journal-title":"Neurotherapeutics"},{"key":"10065_CR12","doi-asserted-by":"publisher","first-page":"R1282","DOI":"10.1016\/j.cub.2023.10.016","volume":"33","author":"N Kolbman","year":"2023","unstructured":"Kolbman, N. et al. Intravenous psilocybin attenuates mechanical hypersensitivity in a rat model of chronic pain. Curr. Biol. 33, R1282\u2013R1283 (2023).","journal-title":"Curr. Biol."},{"key":"10065_CR13","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1136\/rapm-2020-101273","volume":"45","author":"JP Castellanos","year":"2020","unstructured":"Castellanos, J. P. et al. Chronic pain and psychedelics: a review and proposed mechanism of action. Reg. Anesth. Pain. Med. 45, 486\u2013494 (2020).","journal-title":"Reg. Anesth. Pain. Med."},{"key":"10065_CR14","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1093\/brain\/awt211","volume":"136","author":"JA Hashmi","year":"2013","unstructured":"Hashmi, J. A. et al. Shape shifting pain: chronification of back pain shifts brain representation from nociceptive to emotional circuits. Brain 136, 2751\u20132768 (2013).","journal-title":"Brain"},{"key":"10065_CR15","doi-asserted-by":"publisher","unstructured":"Askey, T., Lasrado, R., Maiar\u00fa, M. & Stephens, G. J. Psilocybin as a novel treatment for chronic pain. Br. J. Pharmacol. 1\u201314, https:\/\/doi.org\/10.1111\/bph.17420 (2024).","DOI":"10.1111\/bph.17420"},{"key":"10065_CR16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0304-3959(00)00276-1","volume":"87","author":"I Decosterd","year":"2000","unstructured":"Decosterd, I. & Woolf, C. J. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 87, 149\u2013158 (2000).","journal-title":"Pain"},{"key":"10065_CR17","doi-asserted-by":"crossref","unstructured":"Pertin, M., Gosselin, R.-D. & Decosterd, I. The spared nerve injury model of neuropathic pain. in Pain Research (ed. Luo, Z. D.), Vol. 851, 205\u2013212 (Humana Press, 2012).","DOI":"10.1007\/978-1-61779-561-9_15"},{"key":"10065_CR18","doi-asserted-by":"publisher","first-page":"107933","DOI":"10.1016\/j.neuropharm.2019.107933","volume":"167","author":"AL Halberstadt","year":"2020","unstructured":"Halberstadt, A. L., Chatha, M., Klein, A. K., Wallach, J. & Brandt, S. D. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. Neuropharmacology 167, 107933 (2020).","journal-title":"Neuropharmacology"},{"key":"10065_CR19","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","volume":"109","author":"L-X Shao","year":"2021","unstructured":"Shao, L.-X. et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron 109, 2535\u20132544.e4 (2021).","journal-title":"Neuron"},{"key":"10065_CR20","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1021\/acschemneuro.0c00013","volume":"11","author":"J Caporoso","year":"2020","unstructured":"Caporoso, J. et al. A thermal place preference test for discovery of neuropathic pain drugs. ACS Chem. Neurosci. 11, 1006\u20131012 (2020).","journal-title":"ACS Chem. Neurosci."},{"key":"10065_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-95916-5","volume":"11","author":"K Matsumoto","year":"2021","unstructured":"Matsumoto, K. et al. Juvenile social defeat stress exposure favors in later onset of irritable bowel syndrome-like symptoms in male mice. Sci. Rep. 11, 16276 (2021).","journal-title":"Sci. Rep."},{"key":"10065_CR22","doi-asserted-by":"publisher","first-page":"14148","DOI":"10.3390\/ijms232214148","volume":"23","author":"O Shahar","year":"2022","unstructured":"Shahar, O. et al. Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 receptors in the head twitch response induced by 5-hydroxytryptophan and psilocybin: translational implications. IJMS 23, 14148 (2022).","journal-title":"IJMS"},{"key":"10065_CR23","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1007\/s00213-022-06092-x","volume":"239","author":"AM Jaster","year":"2022","unstructured":"Jaster, A. M. et al. Effects of the 5-HT2A receptor antagonist volinanserin on head-twitch response and intracranial self-stimulation depression induced by different structural classes of psychedelics in rodents. Psychopharmacology 239, 1665\u20131677 (2022).","journal-title":"Psychopharmacology"},{"key":"10065_CR24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.vascn.2014.07.003","volume":"70","author":"R Haberzettl","year":"2014","unstructured":"Haberzettl, R., Fink, H. & Bert, B. Role of 5-HT1A- and 5-HT2A receptors for the murine model of the serotonin syndrome. J. Pharmacol. Toxicol. Methods 70, 129\u2013133 (2014).","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10065_CR25","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.65156","volume":"10","author":"RA Drake","year":"2021","unstructured":"Drake, R. A., Steel, K. A., Apps, R., Lumb, B. M. & Pickering, A. E. Loss of cortical control over the descending pain modulatory system determines the development of the neuropathic pain state in rats. eLife 10, e65156 (2021).","journal-title":"eLife"},{"key":"10065_CR26","doi-asserted-by":"publisher","first-page":"e106133","DOI":"10.1371\/journal.pone.0106133","volume":"9","author":"MN Baliki","year":"2014","unstructured":"Baliki, M. N., Mansour, A. R., Baria, A. T. & Apkarian, A. V. Functional reorganization of the default mode network across chronic pain conditions. PLoS ONE 9, e106133 (2014).","journal-title":"PLoS ONE"},{"key":"10065_CR27","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1126\/science.aap8586","volume":"363","author":"G Corder","year":"2019","unstructured":"Corder, G. et al. An amygdalar neural ensemble that encodes the unpleasantness of pain. Science 363, 276\u2013281 (2019).","journal-title":"Science"},{"key":"10065_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-68763-z","volume":"17","author":"NS Gregory","year":"2026","unstructured":"Gregory, N. S. et al. No evidence of immediate or persistent analgesic effect from a single dose of psilocybin in three mouse models of pain. Nat. Commun. 17, 1916 (2026).","journal-title":"Nat. Commun."},{"key":"10065_CR29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jpain.2023.02.034","volume":"24","author":"E Koseli","year":"2023","unstructured":"Koseli, E. et al. Effect of hallucinogenic and non-hallucinogenic psychedelic analogs on chronic neuropathic pain in mice.  J. Pain. 24, 6\u20137 (2023).","journal-title":"J. Pain."},{"key":"10065_CR30","doi-asserted-by":"publisher","unstructured":"Askey, T. et al. Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesia. Preprint at. https:\/\/doi.org\/10.1101\/2025.09.15.676273 (2025).","DOI":"10.1101\/2025.09.15.676273"},{"key":"10065_CR31","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.3390\/ijms21093396","volume":"21","author":"F Guida","year":"2020","unstructured":"Guida, F. et al. Behavioral, biochemical and electrophysiological changes in spared nerve injury model of neuropathic pain. IJMS 21, 3396 (2020).","journal-title":"IJMS"},{"key":"10065_CR32","doi-asserted-by":"publisher","first-page":"5926","DOI":"10.1038\/s41380-025-03169-9","volume":"30","author":"AJ Drewko","year":"2025","unstructured":"Drewko, A. J., Habets, R. L. P. & Brunt, T. M. Above the threshold, beyond the trip: the role of the 5-HT2A receptor in psychedelic-induced neuroplasticity and antidepressant effects. Mol. Psychiatry 30, 5926\u20135937 (2025).","journal-title":"Mol. Psychiatry"},{"key":"10065_CR33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2022489118","volume":"118","author":"N Hesselgrave","year":"2021","unstructured":"Hesselgrave, N., Troppoli, T. A., Wulff, A. B., Cole, A. B. & Thompson, S. M. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc. Natl. Acad. Sci. USA. 118, e2022489118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10065_CR34","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2023.535","volume":"9","author":"MI Husain","year":"2023","unstructured":"Husain, M. I. et al. Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial. BJPsych Open 9, e134 (2023).","journal-title":"BJPsych Open"},{"key":"10065_CR35","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","volume":"9","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., B\u00e4bler, A., Vogel, H. & Hell, D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 9, 3897\u20133902 (1998).","journal-title":"NeuroReport"},{"key":"10065_CR36","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41386-023-01545-z","volume":"48","author":"A Torrado Pacheco","year":"2023","unstructured":"Torrado Pacheco, A., Olson, R. J., Garza, G. & Moghaddam, B. Acute psilocybin enhances cognitive flexibility in rats. Neuropsychopharmacology 48, 1011\u20131020 (2023).","journal-title":"Neuropsychopharmacology"},{"key":"10065_CR37","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","volume":"26","author":"A Rickli","year":"2016","unstructured":"Rickli, A., Moning, O. D., Hoener, M. C. & Liechti, M. E. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur. Neuropsychopharmacol. 26, 1327\u20131337 (2016).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10065_CR38","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.tins.2024.08.011","volume":"47","author":"CA Brunello","year":"2024","unstructured":"Brunello, C. A., Cannarozzo, C. & Castr\u00e9n, E. Rethinking the role of TRKB in the action of antidepressants and psychedelics. Trends Neurosci. 47, 865\u2013874 (2024).","journal-title":"Trends Neurosci."},{"key":"10065_CR39","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","volume":"26","author":"Moliner","year":"2023","unstructured":"Moliner et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat. Neurosci. 26, 1032\u20131041 (2023).","journal-title":"Nat. Neurosci."},{"key":"10065_CR40","doi-asserted-by":"crossref","unstructured":"Wiffen, P. J. et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst. Rev. 6, CD007938 (2017).","DOI":"10.1002\/14651858.CD003726.pub4"},{"key":"10065_CR41","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.euroneuro.2017.08.430","volume":"27","author":"U Bonnet","year":"2017","unstructured":"Bonnet, U. & Scherbaum, N. How addictive are gabapentin and pregabalin? A systematic review. Eur. Neuropsychopharmacol. 27, 1185\u20131215 (2017).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10065_CR42","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41386-022-01389-z","volume":"48","author":"AE Calder","year":"2023","unstructured":"Calder, A. E. & Hasler, G. Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology 48, 104\u2013112 (2023).","journal-title":"Neuropsychopharmacology"},{"key":"10065_CR43","doi-asserted-by":"publisher","DOI":"10.1126\/science.ado6593","volume":"385","author":"MP Fatt","year":"2024","unstructured":"Fatt, M. P. et al. Morphine-responsive neurons that regulate mechanical antinociception. Science 385, eado6593 (2024).","journal-title":"Science"},{"key":"10065_CR44","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1152\/physrev.00045.2019","volume":"101","author":"NB Finnerup","year":"2021","unstructured":"Finnerup, N. B., Kuner, R. & Jensen, T. S. Neuropathic pain: from mechanisms to treatment. Physiol. Rev. 101, 259\u2013301 (2021).","journal-title":"Physiol. Rev."},{"key":"10065_CR45","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0304-3959(02)00039-8","volume":"98","author":"HK Erichsen","year":"2002","unstructured":"Erichsen, H. K. & Blackburn-Munro, G. Pharmacological characterisation of the spared nerve injury model of neuropathic pain. Pain 98, 151\u2013161 (2002).","journal-title":"Pain"},{"key":"10065_CR46","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0014-4886(03)00097-9","volume":"182","author":"H Gustafsson","year":"2003","unstructured":"Gustafsson, H. et al. Gabapentin reverses mechanical allodynia induced by sciatic nerve ischemia and formalin-induced nociception in mice. Exp. Neurol. 182, 427\u2013434 (2003).","journal-title":"Exp. Neurol."},{"key":"10065_CR47","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1111\/bph.15193","volume":"177","author":"N Percie Du Sert","year":"2020","unstructured":"Percie Du Sert, N. et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. Br. J. Pharmacol. 177, 3617\u20133624 (2020).","journal-title":"Br. J. Pharmacol."},{"key":"10065_CR48","doi-asserted-by":"crossref","unstructured":"Maiar\u00f9, M. et al. Substance P-botulinum mediates long-term silencing of pain pathways that can be re-instated with a second injection of the construct in mice. J. Pain 25, 104466 (2024).","DOI":"10.1016\/j.jpain.2024.01.331"},{"key":"10065_CR49","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0165-0270(94)90144-9","volume":"53","author":"SR Chaplan","year":"1994","unstructured":"Chaplan, S. R., Bach, F. W., Pogrel, J. W., Chung, J. M. & Yaksh, T. L. Quantitative assessment of tactile allodynia in the rat paw. J. Neurosci. Methods 53, 55\u201363 (1994).","journal-title":"J. Neurosci. Methods"},{"key":"10065_CR50","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.cell.2014.11.003","volume":"159","author":"B Duan","year":"2014","unstructured":"Duan, B. et al. Identification of spinal circuits transmitting and gating mechanical pain. Cell 159, 1417\u20131432 (2014).","journal-title":"Cell"},{"key":"10065_CR51","doi-asserted-by":"publisher","first-page":"325ra19","DOI":"10.1126\/scitranslmed.aab3376","volume":"8","author":"M Maiar\u00f9","year":"2016","unstructured":"Maiar\u00f9, M. et al. The stress regulator FKBP51 drives chronic pain by modulating spinal glucocorticoid signaling. Sci. Transl. Med. 8, 325ra19 (2016).","journal-title":"Sci. Transl. Med."},{"key":"10065_CR52","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jpain.2012.02.009","volume":"13","author":"C Mills","year":"2012","unstructured":"Mills, C. et al. Estimating efficacy and drug ED50\u2019s using von Frey thresholds: impact of Weber\u2019s law and log transformation.  J. Pain. 13, 519\u2013523 (2012).","journal-title":"J. Pain."},{"key":"10065_CR53","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar7384","volume":"10","author":"M Maiar\u00f9","year":"2018","unstructured":"Maiar\u00f9, M. et al. Selective neuronal silencing using synthetic botulinum molecules alleviates chronic pain in mice. Sci. Transl. Med. 10, eaar7384 (2018).","journal-title":"Sci. Transl. Med."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10065-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10065-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10065-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T13:02:24Z","timestamp":1779714144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10065-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10065"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-10065-7","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"707"}}